Clinical Trials
13 trialsNCT06954480 2026-05-22
DIAMOND
Queen Mary University of London
Phase 2 Recruiting
NCT03606967 2026-05-13
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT05582538 2025-08-24
ATRiBRAVE
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Recruiting
NCT03740893 2025-08-11
PHOENIX
Institute of Cancer Research, United Kingdom
Phase 2 Recruiting
NCT05215106 2024-07-08
POP-DURVA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT05209529 2024-02-23
Chemo-free BRCA-targeted Neoadjuvant Strategy
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT02527434 2023-11-15
Study of Tremelimumab in Patients With Advanced Solid Tumors
AstraZeneca
Phase 2 Completed
NCT03982173 2023-01-26
MATILDA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Withdrawn
NCT03167619 2022-09-13
DORA
Duke University
Phase 2 Completed
NCT03872505 2021-08-25
PANDoRA
Cedars-Sinai Medical Center
Phase 2 Withdrawn
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown